Abliva AB (Nasdaq Stockholm: ABLI) – today, 23 June 2020, holds a virtual Capital Markets Day. The theme of the day will be the company's new strategic focus on primary mitochondrial disease, the most important pharmaceutical projects and the market potential.
Program (approximate time):
3:00 p.m. Introduction CEO Erik Kinnman.
3:10 p.m. Medical need and the science CMO Magnus Hansson.
3:25 p.m. Development activities Director Clinical and Regulatory Affairs, Matilda Hugerth.
3:35 p.m. Interview with CEO Erik Kinnman.
3:45 p.m. Interview with Roger Franklin, partner Hadean Ventures, new owner and board member.
3:50 p.m. Questions and Answers from analysts and received via firstname.lastname@example.org.
Approx. 4:30 p.m. Conclusions.
The Capital Markets Day is moderated by Charlotte Stjerngren, Cord Communications. The presentation material will be in English, but the lectures will mainly be held in Swedish.
The Capital Markets Day can be followed via Abliva's website at: http://abliva.com/sv/investor/capital-markets-day-2020/. The recording will also be posted afterwards.
Questions can be asked to email@example.com.